Table 3. The correlation between SNHG7 expression and clinicopathological features.
| Clinicopathological features | No. of studies | No. of patients | OR (95% CI) | P | Heterogeneity | Model | |
| I2 | P-value | ||||||
| Age (≥60 vs. <60) | 7 | 555 | 1.10 (0.77–1.55) | 0.604 | 0.0% | 0.714 | Fixed |
| Gender (Female vs. male) |
11 | 873 | 1.26 (0.95–1.69) | 0.113 | 0.0% | 0.800 | Fixed |
| TNM stage (III–IV vs. I–II) |
6 | 515 | 3.31 (2.29–4.80) | 0.000 | 18.5% | 0.293 | Fixed |
| Lymph node metastases (Positive vs. negative) |
10 | 685 | 3.32 (1.61–6.83) | 0.001 | 75% | 0.000 | Random |
| Distant metastasis (Positive vs. negative) |
6 | 478 | 1.54 (0.41–5.72) | 0.522 | 84.8% | 0.000 | Random |
| Tumor differentiation (Poor vs. Moderate/Well) |
5 | 320 | 1.92 (1.22–3.03) | 0.005 | 13.9% | 0.325 | Fixed |